title: Diagnostic testing, treatment, cost of care, and survival among registered and non-registered patients with myelodysplastic syndromes.
abstract: Considering current reliance on cancer registry data, we sought to assess the potential for bias in myelodysplastic syndrome (MDS) registration using SEER-Medicare data 2001-2005. Using a validated claims-based algorithm, we identified and compared registered and non-registered MDS patients, and found that median cumulative survival was 18 and 28 months, 74% and 64% used erythropoiesis-stimulating agents (ESAs), and average 6-month health care cost was $24,249 and $21,750, respectively. While most non-registered MDS patients showed resource utilization and survival characteristics consistent with lower-risk MDS, a subset was registered as acute myeloid leukemia (7.6%) and accounted for early mortality.
authors.affiliation: Health Outcomes & Behavior, H. Lee Moffitt Cancer Center & Research Institute, MRC-CANCONT, Tampa, FL 33612-9416, USA. benjamin.craig@moffitt.org
authors.forename: Benjamin M
authors.initials: BM
authors.lastname: Craig
authors.forename: Dana E
authors.initials: DE
authors.lastname: Rollison
authors.forename: Alan F
authors.initials: AF
authors.lastname: List
authors.forename: Christopher R
authors.initials: CR
authors.lastname: Cogle
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D003955:Diagnostic Tests, Routine / Q000191:economics*; D005260:Female; D017048:Health Care Costs; D006397:Hematinics / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000191:economics / Q000401:mortality; D008297:Male; D006278:Medicare / Q000191:economics*; D009190:Myelodysplastic Syndromes / Q000175:diagnosis / Q000188:drug therapy / Q000191:economics* / Q000401:mortality*; D012189:Retrospective Studies; D018426:SEER Program; D015996:Survival Rate; D014481:United States
chemical_list: D006397:Hematinics